Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) dropped 1.3% during trading on Monday . The stock traded as low as $8.38 and last traded at $8.43, with a volume of 592,595 shares traded. The stock had previously closed at $8.54.

Several analysts recently issued reports on the company. Zacks Investment Research upgraded Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a report on Thursday, May 5th. Jefferies Group reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a report on Tuesday, August 9th. Leerink Swann reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a report on Sunday, June 12th. JMP Securities upgraded Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price objective for the company in a report on Thursday, July 7th. Finally, Robert W. Baird reiterated an “outperform” rating and set a $10.00 price objective on shares of Achillion Pharmaceuticals in a report on Monday, June 6th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $9.63.

The company has a market cap of $1.15 billion and a P/E ratio of 171.43. The firm’s 50-day moving average is $8.73 and its 200-day moving average is $8.28.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same quarter in the prior year, the firm posted ($0.25) EPS. Equities research analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.63) EPS for the current year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.